Tubuloglomerular feedback (TGF) is a renal autoregulatory mechanism that constricts the afferent arteriole in response to increases in distal NaCl. Heme oxygenases (HO-1 and HO-2) release carbon monoxide (CO) and biliverdin, which may help control renal function. We showed in vitro that HO products inhibit TGF; however, we do not know whether this also occurs in vivo or the mechanism(s) involved. We hypothesized that in vivo HO-1 and HO-2 in the nephron inhibit TGF via release of CO and biliverdin. We first performed laser capture microdissection followed by real-time PCR and found that both HO-1 and HO-2 are expressed in the macula densa. We next performed micropuncture experiments in vivo on individual rat nephrons, adding different compounds to the perfusate, and found that an HO inhibitor, stannous mesoporphyrin (SnMP), potentiated TGF (P Ͻ 0.05, SnMP vs. control). The CO-releasing molecule (CORM)-3 partially inhibited TGF at 50 mol/l (P Ͻ 0.01, CORM-3 vs. control) and blocked it completely at higher doses. A soluble guanylyl cyclase (sGC) inhibitor, LY83583, blocked the inhibitory effect of CORM-3 on TGF. Biliverdin also partially inhibited TGF (P Ͻ 0.01, biliverdin vs. control), most likely attributable to decreased superoxide (O 2 Ϫ ) because biliverdin was rendered ineffective by tempol, a O 2 Ϫ dismutase mimetic. We concluded that HO-1 and HO-2 in the nephron inhibit TGF by releasing CO and biliverdin. The inhibitory effect of CO on TGF is mediated by the sGC/cGMP signaling pathway, whereas biliverdin probably acts by reducing O 2 Ϫ .
mainly within epithelial cells of the thick ascending limb, distal convoluted and connecting tubules, and preglomerular arterioles (8, 12) . HO-1 is normally low and contributes to HO activity only when it is induced as a result of some pathological condition (8) . In vivo studies suggest that endogenous HO products can cause renal vasodilatation, diuresis, and natriuresis because metalloporphyrins (which inhibit HOs) increase blood pressure (14) and decrease renal blood flow (25, 42) , glomerular filtration rate (4) , and pressure natriuresis (18) .
CO bears numerous similarities to NO. They are both gasotransmitters, small gaseous molecules that readily diffuse across membranes; they are not usually stored and do not bind to classical membrane receptors. Both CO and NO stimulate soluble guanylyl cyclase (sGC) and potassium channels (39) , and both can influence vascular tone, platelet aggregation, and vascular smooth muscle proliferation (for a review, see Ref. 40 ). Therefore, it seems reasonable that CO would inhibit TGF just like NO. In addition, the HO/CO/biliverdin system (HO system) provides strong antioxidant protection, converting the prooxidant heme into biliverdin, which together with its immediate derivative bilirubin, is a potent antioxidant (6, 36) that can directly react with O 2 Ϫ (32). We have evidence that in vitro (isolated perfused MD and attached Af-Art) the HO system inhibits TGF (29) . However, we do not know whether it helps regulate TGF in vivo or the mechanism(s) involved. We hypothesized that 1) in vivo the HO system inhibits TGF by releasing CO and biliverdin, 2) the inhibitory effect of CO on TGF is mediated by the sGC/cGMP signaling pathway, and 3) biliverdin acts by decreasing O 2 Ϫ .
MATERIALS AND METHODS
All experiments were approved by the Henry Ford Health System Institutional Animal Care and Use Committee and were conducted in accord with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
Laser capture microdissection. We used similar methods to isolate MD cells with laser capture microdissection (LCM) as we described recently (41) . For this, Sprague-Dawley rats weighing 100 -120 g were anesthetized with ketamine (50 mg/kg ip) and xylazine (50 mg/kg ip). The abdomen was opened, and the kidneys were removed. Sections were snap frozen in optimal-cutting-temperature medium using an isopentane bath, after which 8-m frozen sections were stained and dehydrated using a Histogene frozen-section staining kit (Arcturus Engineering, Mountain View, CA) according to the manufacturer's instructions and viewed with a PixCell II LCM system (Arcturus). MD cells were identified by their location and morphology and dissected with the laser under a ϫ60 objective, using a laser power of 45 mW, pulse 2,500 -3,000 s, and intensity 200 mV.
LCM caps were snapped onto 0.5-ml microcentrifuge tubes containing guanidine isothiocyanate buffer for RNA extraction. Total RNA was isolated using a PicoPure kit (Arcturus), and complementary DNA synthesis was carried out using random primers (Invitrogen, Carlsbad, CA) and a MessageSensorTM RT kit (Ambion, Austin, TX) according to the manufacturers' instructions. Real-time PCR was performed with an iCycler 1 system (Bio-Rad, Hercules, CA) for 3 min at 95°C followed by 40 cycles of melting for 30 s at 94°C, annealing for 30 s at 58°C, and extension for 45 s at 72°C. Data were analyzed with IQTM5 optical system software (Bio-Rad). ␤-Actin was used as a housekeeping gene. Captured MD cells were confirmed by positive expression of neuronal NO synthase (41) . The following primers were used: HO-1 forward, 5=-TCCAGACACCGCTCCTC-CAG-3=; HO-1 reverse, 5=-GGATTTG-GGGCTGCTGGTTTC-3=; HO-2 forward, 5=-TACTTCACATACTCAGCCCT-3=; HO-2 reverse, 5=-ATGGGCCACCAGCAGCTCTG-3=.
Micropuncture experiments. Male Sprague-Dawley rats (225-380 g body wt) were anesthetized with thiobutabarbital (125 mg/kg body wt). Body temperature was maintained at 37.5°C using a feedbackcontrolled, heated surgical table. A tracheotomy was performed with PE-240 tubing to allow spontaneous breathing of room air. The right jugular vein was catheterized with PE-10 tubing for maintenance infusion of 0.9% NaCl at a rate of 1.5 ml/h. The left femoral artery was catheterized with PE-10 tubing attached to a pressure transducer and recorder and blood pressure monitored continuously. The left kidney was approached through a flank incision, freed of adherent fat and connective tissue, and placed in a Lucite cup, eliminating the effects of body movement. It was then bathed in saline and immobilized by surrounding it loosely with saline-soaked cotton. The bladder was cannulated to allow free urine flow. After a 30-to 45-min equilibration period, proximal tubules were identified by injecting 7% FD&C green phosphate buffer (pH 7.4) into a random proximal segment with a glass pipette (OD 6 -8 m at the tip). A nephron was used when at least two downstream proximal segments were identified, indicating an early proximal puncture site. Early proximal portions were blocked with grease, and a perfusion pipette (OD 8 -10 m) attached to a nanoliter infusion pump was inserted into the last superficial proximal segment to perfuse the loop of Henle with an artificial tubule perfusion solution containing (in mmol/l): 140 NaCl, 10 HEPES, 1 CaCO 3, 0.5 K2HPO4, 4 KHCO3, 1.2 MgSO4, 5.5 glucose, 0.5 sodium acetate, 0.5 sodium lactate, and 0.5% FD&C green dye (pH 7.4). To measure stop-flow pressure (PSF), a pressure pipette (OD 3-4 m) attached to a micropressure system (model 900A; World Precision Instruments, Sarasota, FL) was inserted into an early proximal segment. Perfusion of the late proximal tubule was increased from 0 to 10, 20, 30, and 40 nl/min, and first P SF doseresponse curves (DRCs) were generated, maintaining each rate for 1-5 min to obtain a stable P SF. The tubular perfusate was then changed to the compounds being studied, and a second and third PSF DRC were generated.
Stannous mesoporphyrin (SnMP), an HO inhibitor, was purchased from Frontier Scientific (Logan, UT). A stock solution of 2 mmol/l SnMP was prepared by sonication in alkaline vehicle (50 mmol/l Na2CO3), resulting in a dark purple solution. Dilution of SnMP (75 l in 10 ml) to its final concentration (15 mol/l) in the perfusion solution resulted in a clear, slightly purple liquid with no precipitation. The solution was filtered immediately before use with a 0.45-m syringe filter. Adding SnMP did not significantly change the pH (7.3 vs. 7.33). Sodium concentration was increased by 0.75 mmol/l because of the sodium content in the SnMP stock solution, which did not affect the TGF response (27) . Tricarbonylchloro(glycinato)ruthenium(II), known as CO-releasing molecule 3 (CORM-3, synthesized and provided by J. R. Falck, Dallas, TX), was used as a CO donor. This was freshly prepared before the experiments by dissolving the compound in distilled water. The final concentration was 0.5-1.0%, which did not affect thick ascending limb or MD function (29) . Biliverdin was obtained from MP Biomedicals, Solon, OH. Tempol (4-hydroxy-TEMPO), a O 2 Ϫ dismutase mimetic, was purchased from Sigma (St. Louis, MO). LY83583, an sGC inhibitor, was purchased from Enzo Biochem (Farmingdale, NY).
We generated two or three consecutive PSF DRCs by increasing the late proximal tubule perfusion rate (0, 10, 20, 30, and 40 nl/min) in the same preparation and recording PSF at each flow rate, taking the first PSF DRC as a control.
Statistics. Data are expressed as means Ϯ SE. Student's paired t-test was used to compare PSF for each flow rate between control and experimental conditions. Hochberg's step-up procedure was used to adjust the P values for multiple comparisons and control the familywise type I error rate, predefined as 0.05.
RESULTS
Using LCM followed by real-time PCR, we found that both HO-1 and HO-2 were expressed in MD cells. The threshold cycle (C t ) of HO-1 was 33.5 Ϯ 0.56; HO-2 was 31.4 Ϯ 0.61 (P Ͻ 0.05); and ␤-actin was 24.5 Ϯ 0.47 (n ϭ 3), indicating higher MD expression of HO-2 than HO-1.
For the micropuncture experiments, we first tested whether TGF varied over time. When late proximal perfusion rate was increased from 0 to 10, 20, 30, and 40 nl/min, P SF decreased from 39.1 Ϯ 0.9 to 38.8 Ϯ 0.8, 36.5 Ϯ 0.6, 31.8 Ϯ 0.8, and 31.1 Ϯ 0.6 mmHg, respectively. The second and third responses were not significantly different (n ϭ 6 rats/8 tubules; Fig. 1 ).
To determine whether endogenous HOs help regulate TGF in vivo, we generated two consecutive P SF DRCs, obtaining the second curve after adding 15 mol/l SnMP to the tubular perfusate. We found that P SF at 20 and 30 nl/min fell much farther when SnMP was present (n ϭ 6 rats/8 tubules; Fig. 2 ). Because HOs release CO from heme, we examined the effect of adding CORM-3, a CO-releasing molecule, to the tubular perfusate on P SF . We found that 50 mol/l CORM-3 blunted the decrease in P SF significantly at 20, 30, and 40 nl/min (n ϭ 6 rats/9 tubules; Fig. 3A ), whereas 100 mol/l CORM-3 blocked it completely (n ϭ 6 rats/9 tubules; Fig. 3B ).
CO reportedly increases renal blood flow by stimulating sGC (33). Thus we tested the effect of CORM-3 (50 mol/l) on P SF in the presence of the sGC inhibitor LY83583 (1 mol/l). As expected, LY83583 enhanced the decrease in P SF induced by late proximal tubule perfusion; however, when LY83583 was present CORM-3 was ineffective (n ϭ 6 rats/6 tubules; Fig. 4A ). As a further control, we repeated this experiment but washed out the LY83583 before adding the CORM-3. Once the LY83583 was removed, CORM-3 significantly increased P SF (n ϭ 6 rats/6 tubules; Fig. 4B ).
Because HOs also release biliverdin from heme, we tested whether biliverdin also regulates it. In the presence of biliverdin, the decrease in P SF was significantly blunted at 20, 30, and 40 nl/min (n ϭ 6 rats/10 tubules; Fig. 5 ). HO-derived biliverdin and bilirubin are potent antioxidants (6, 36) that can directly react with O 2 Ϫ (32), and we have shown that O 2 Ϫ in the MD potentiates TGF (28) . Therefore, we tested whether biliverdin inhibits TGF by scavenging O 2 Ϫ . We first examined the effect of the O 2 Ϫ dismutase mimetic tempol (100 mol/l) on P SF responses. As expected, tempol blunted the decrease in P SF significantly at 20, 30, and 40 nl/min (n ϭ 6 rats/11 tubules; Fig. 6A ). We then tested the effect of biliverdin on P SF in the presence of tempol. In the presence of tempol, biliverdin had no effect on P SF (n ϭ 6 rats/10 tubules; Fig. 6B ).
DISCUSSION
Using LCM followed by real-time PCR, we found that both HO-1 and HO-2 are expressed in the MD. Furthermore, using in vivo renal micropuncture, we obtained evidence supporting our hypothesis that in vivo the HO system inhibits TGF by releasing CO and biliverdin. Blocking tubular HOs with SnMP potentiated TGF, whereas adding exogenous CO or biliverdin to the tubular perfusate inhibited it. Furthermore, the effect of CO was mediated by activating the sGC/cGMP signaling pathway, whereas the effect of biliverdin was mediated by decreasing O 2 Ϫ , suggesting that the HO system plays a significant role in TGF regulation.
Research of the MD has been hindered by the difficulty in acquiring MD cells in quantities sufficient enough to perform the necessary biochemical analysis required to study cellular and molecular mechanisms. We took advantage of the recent development of LCM(10) to successfully harvest MD cells from frozen sections and measured mRNAs with single-cell RT-PCR. This is the first demonstration that the MD expresses HO. We found both HO-1 and HO-2, which is an interesting finding because HO-1 is normally considered inducible, although not entirely surprising if one considers that "inducible" cyclooxygenase-2 is expressed in the MD under baseline conditions (23) .
We recently showed that in vitro CO and biliverdin inhibit TGF and SnMP potentiates it (29) . In the present study, we confirmed that this also occurs in vivo and were able to determine how CO and biliverdin inhibit TGF. Using a specific HO inhibitor, SnMP, which selectively lowers HO activity without affecting NO synthase (20) , we examined the role of endogenous CO and biliverdin in TGF regulation. Adding SnMP to the tubular perfusate potentiated TGF, indicating that the endogenous HO system in the MD attenuates TGF.
Botros et al. (7) recently showed that an HO inhibitor applied directly to the Af-Art does not affect basal Af-Art tone, but we found that the HO inhibitor SnMP does affect TGFinduced constriction of the Af-Art when applied in the lumen of the attached MD. This suggests that the effect of SnMP we observed is not attributable to diffusion to the Af-Art but to an inhibition of TGF acting locally in the MD.
To determine which HO metabolite(s) might attenuate TGFinduced Af-Art constriction, we questioned whether adding exogenous CO or biliverdin could inhibit TGF. CO is a versatile signaling molecule that is essential for regulation of many different physiological and pathophysiological processes (40) . CORM-3 liberates CO in a concentration-dependent manner both in vitro and in vivo (22) . In our study, CORM-3 inhibited TGF in a dose-dependent manner, blunting the TGF response at 50 mol/l and blocking it completely at higher doses. CO activates sGC (21) , and activation of sGC in the MD is known to inhibit TGF (30) . We found that blocking sGC suppressed the inhibitory effect of CO on TGF, suggesting that CO inhibits TGF via the sGC/cGMP signaling pathway. On the other hand, CO was recently shown to decrease O 2 Ϫ in a mouse thick ascending limb cell line (15) , and, if that were to occur in the MD, it would also indirectly block TGF by increasing NO availability. However, this is unlikely because our recent in vitro study showed that CO inhibition of TGF is independent of NO synthase blockade (29) .
CO at high concentrations inhibits cytochrome c oxidase in the electron transport chain and is toxic to the mitochondria (5); thus it could be argued that CORM-3 inhibits TGF by damaging the MD. However, we found that CORM-3 was rendered completely ineffective by the sGC inhibitor LY83583, and we have previously shown in vitro that the effect of CORM-3 on TGF is reversible (29) . It could also be argued that CO may act by diffusing to the Af-Art, where it would cause direct vasodilation, instead of acting through the MD. However, because intraluminal administration of the sGC inhibitor LY83583 completely blocks the effect of CO and because we have previously shown that LY83583 does not diffuse to the Af-Art when applied to the lumen of the MD (30), we conclude that CO acts on the MD to inhibit TGF.
One limitation of the micropuncture technique we used is that concentrations of a gas such as CO that actually reach the MD may be significantly lower than that present in the perfusate of the late proximal tubule because a gas is capable of diffusing across membranes and binding to tissue heme proteins or even being carried out of the kidney in the hemoglobin of the red blood cells. Another limitation is the fact that the physiological concentration of CO in tissue is not well established (40) . Nevertheless, we were able to confirm the existence of a nontoxic concentration of CO that inhibits TGF by modulating endogenous cGMP production. Furthermore, because SnMP potentiated TGF, we can conclude that endogenous physiological concentrations of HO products will attenuate TGF.
HOs release not only CO but also biliverdin, which is rapidly metabolized to bilirubin by biliverdin reductase (1, 3) . Although long considered simply a waste product of heme degradation, biliverdin/bilirubin may actually offer some degree of protection against cardiovascular disease. In the Framingham prospective cohort study, higher serum bilirubin concentrations were associated with a lower risk of cardiovascular disease in men (9) . In patients with Gilbert syndrome, which is characterized by lifelong moderate hyperbilirubinemia, there is a lower risk of diabetic complications (13) and ischemic heart disease (37). In rats, bilirubin can prevent some of the effects of angiotensin II infusion (17, 26) , perhaps because biliverdin and bilirubin are potent antioxidants (6, 36) that can inhibit NADPH oxidase (16) and directly scavenge O 2 Ϫ (32). Our previous in vitro study showed that biliverdin inhibits the TGF induced by high NaCl (29) . In the present study, we confirmed this is also true in vivo. Because we have shown that O 2 Ϫ produced by NADPH oxidases in the MD potentiates TGF(28), we tested the effect of biliverdin on TGF after adding tempol to the tubular perfusate. As expected we found that tempol lowered the TGF response. Interestingly, biliverdin in the tubular perfusate did not affect TGF when tempol was added, suggesting that biliverdin inhibits TGF by decreasing O 2 Ϫ . These data differ from that of Botros et al. (7), who reported that biliverdin did not affect autoregulation in a TGF preparation. There are at least two important differences in experimental conditions that may easily explain the different results. First, they studied juxtaglomerular nephrons, whereas we studied superficial ones. Second, in their technique drugs are superfused in the bath, whereas in ours they are perfused inside the tubule.
In summary, we believe this is the first reported demonstration that in vivo the endogenous HO system attenuates TGFinitiated Af-Art constriction. Blocking endogenous HOs potentiated TGF, whereas adding either CO or biliverdin to the luminal side of the nephron blunted TGF. Furthermore, the effect of biliverdin could be prevented by pretreatment with a O 2 Ϫ scavenger, whereas the effect of CO could be eliminated by inhibiting sGC. Thus we believe the HO system in the nephron inhibits the TGF response by releasing CO and biliverdin; CO activates the sGC/cGMP signaling pathway, and biliverdin decreases O 2 Ϫ . Inhibition of TGF by the HO system represents a novel mechanism of renal blood flow regulation. When dietary salt intake is high, inhibition of TGF by the HO system would reduce Af-Art constriction, allowing Na ϩ excretion. Under physiological conditions, integrity of the HO system is necessary for pressure natriuresis, as blocking HOs blunts the expected increase in Na excretion in response to increases in renal perfusion pressure (18) . Our data suggest that the pressure natriuresis caused by HOs may be mediated in part by resetting or attenuating TGF.
Human studies focusing on polymorphisms in the HO-1 gene suggest a possible role of the HO system in hypertension and cardiovascular disease (11) . In the future, strategies designed to increase activity of HO or its products could be useful in treating cardiovascular disease.
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